Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

pSivida Announces 13 New Patents Issued or Allowed

By Globe Newswire | August 29, 2016

pSivida Corp. announced the  addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016.

This brings the total number of patents issued and applications allowed in the Company’s intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S. and foreign jurisdictions.

Paul Ashton, Ph.D., president and CEO of pSivida, said, “Protection of our intellectual property continues to be extremely important to us. We have successfully secured intellectual property protection for our three FDA-approved products providing sustained drug delivery to the back of the eye and are working to build a solid patent foundation for future products.”

The 13 new patents issued and applications allowed include:

  • Two in the U.S. (both for Tethadur, pSivida’s large-molecule sustained-release delivery technology)
  • Eight in foreign jurisdictions (a total of five for Tethadur in Japan, China and Australia; one for the Medidur injector each in Japan and Hong Kong; and one for Medidur in Japan – Medidur is pSivida’s small molecule sustained release delivery technology)
  • Three design patents for the new smaller needle injector (two in Australia and one in Europe).

With these patents, pSivida’s intellectual property portfolio of issued patents and allowed applications consists of:

  • 10 U.S. and 82 foreign for Durasert
  • 27 U.S. and 88 foreign for Tethadur
  • 5 U.S. and 21 foreign for other pSivida technologies

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!   

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE